A prospective study of risk factors associated with seroprevalence of SARS-CoV-2 antibodies in healthcare workers at a large UK teaching hospital.


Journal

The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424

Informations de publication

Date de publication:
11 2022
Historique:
received: 09 12 2020
revised: 24 08 2022
accepted: 25 08 2022
pubmed: 5 9 2022
medline: 19 10 2022
entrez: 4 9 2022
Statut: ppublish

Résumé

To describe the risk factors for SARS-CoV-2 infection in UK healthcare workers (HCWs). We conducted a prospective sero-epidemiological study of HCWs at a major UK teaching hospital using a SARS-CoV-2 immunoassay. Risk factors for seropositivity were analysed using multivariate logistic regression. 410/5,698 (7·2%) staff tested positive for SARS-CoV-2 antibodies. Seroprevalence was higher in those working in designated COVID-19 areas compared with other areas (9·47% versus 6·16%) Healthcare assistants (aOR 2·06 [95%CI 1·14-3·71]; p=0·016) and domestic and portering staff (aOR 3·45 [95% CI 1·07-11·42]; p=0·039) had significantly higher seroprevalence than other staff groups after adjusting for age, sex, ethnicity and COVID-19 working location. Staff working in acute medicine and medical sub-specialities were also at higher risk (aOR 2·07 [95% CI 1·31-3·25]; p<0·002). Staff from Black, Asian and minority ethnic (BAME) backgrounds had an aOR of 1·65 (95% CI 1·32 - 2·07; p<0·001) compared to white staff; this increased risk was independent of COVID-19 area working. The only symptoms significantly associated with seropositivity in a multivariable model were loss of sense of taste or smell, fever, and myalgia; 31% of staff testing positive reported no prior symptoms. Risk of SARS-CoV-2 infection amongst HCWs is highly heterogeneous and influenced by COVID-19 working location, role, age and ethnicity. Increased risk amongst BAME staff cannot be accounted for solely by occupational factors.

Identifiants

pubmed: 36058413
pii: S0163-4453(22)00514-X
doi: 10.1016/j.jinf.2022.08.030
pmc: PMC9436870
mid: EMS154599
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

557-564

Subventions

Organisme : Wellcome Trust
ID : 207498
Pays : United Kingdom

Informations de copyright

Copyright © 2022. Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Competing interests The authors declare that they have no competing interests

Références

N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
Elife. 2020 Aug 21;9:
pubmed: 32820721
Anaesthesia. 2020 Aug;75(8):989-992
pubmed: 32397005
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Lancet. 2021 May 8;397(10286):1725-1735
pubmed: 33901423
Int J Environ Res Public Health. 2022 Feb 17;19(4):
pubmed: 35206474
Lancet Reg Health Southeast Asia. 2022 Aug;3:100023
pubmed: 35769163
BMJ Glob Health. 2020 Dec;5(12):
pubmed: 33277297
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
Nature. 2021 May;593(7858):266-269
pubmed: 33767447
BMJ Open. 2020 Aug 11;10(8):e039849
pubmed: 32784264
Thorax. 2020 Dec;75(12):1089-1094
pubmed: 32917840
Nat Med. 2020 Aug;26(8):1193-1195
pubmed: 32504052
Am J Epidemiol. 2021 Jan 4;190(1):161-175
pubmed: 32870978
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
Nat Commun. 2021 Feb 10;12(1):905
pubmed: 33568663
Elife. 2020 May 11;9:
pubmed: 32392129
BMJ Open Respir Res. 2020 Sep;7(1):
pubmed: 32873607
Infect Control Hosp Epidemiol. 2021 Apr;42(4):392-398
pubmed: 32962771
Lancet. 2020 Aug 29;396(10251):587-590
pubmed: 32758428
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Clin Microbiol Infect. 2020 Dec;26(12):1690.e1-1690.e4
pubmed: 32898715
Lancet. 2020 Mar 21;395(10228):922
pubmed: 32199474
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
J Hosp Infect. 2020 May;105(1):100-101
pubmed: 32147406
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Influenza Other Respir Viruses. 2020 Jul;14(4):474-475
pubmed: 32246886

Auteurs

Daniel J Cooper (DJ)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Global and Tropical Health Division, Menzies School of Heath Research and Charles Darwin University, Darwin, Northern Territory, Australia; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK. Electronic address: Daniel.cooper@addenbrookes.nhs.uk.

Sara Lear (S)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Laura Watson (L)

NIHR Cambridge Clinical Research Facility.

Ashley Shaw (A)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Mark Ferris (M)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Rainer Doffinger (R)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Rachel Bousfield (R)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Katherine Sharrocks (K)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Michael P Weekes (MP)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Ben Warne (B)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Dominic Sparkes (D)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Clinical Microbiology and Public Health Laboratory, Public Health England, United Kingdom.

Nick K Jones (NK)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Clinical Microbiology and Public Health Laboratory, Public Health England, United Kingdom.

Lucy Rivett (L)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Clinical Microbiology and Public Health Laboratory, Public Health England, United Kingdom.

Matthew Routledge (M)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Clinical Microbiology and Public Health Laboratory, Public Health England, United Kingdom.

Afzal Chaudhry (A)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Katherine Dempsey (K)

NIHR Cambridge Clinical Research Facility.

Montgomery Matson (M)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

Adil Lakha (A)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

George Gathercole (G)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

Olivia O'Connor (O)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

Emily Wilson (E)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

Orthi Shahzad (O)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

Kieran Toms (K)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

Rachel Thompson (R)

University of Cambridge School of Clinical Medicine, Cambridge, UK.

Ian Halsall (I)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

David Halsall (D)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Sally Houghton (S)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Sofia Papadia (S)

NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK; Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Nathalie Kingston (N)

NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK; Department of Haematology, School of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Kathleen E Stirrups (KE)

NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK; Department of Haematology, School of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Barbara Graves (B)

NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK; Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Paul Townsend (P)

NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK.

Neil Walker (N)

NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK; Department of Haematology, School of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Hannah Stark (H)

NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK; Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Daniela De Angelis (D)

MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

Shaun Seaman (S)

MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

Gordon Dougan (G)

Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.

John R Bradley (JR)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; NIHR BioResource, NIHR Cambridge Biomedical Research Centre, Cambridge Biomedical Campus, Cambridge, UK.

M Estée Török (ME)

Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.

Ian Goodfellow (I)

Department of pathology, Division of virology, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.

Stephen Baker (S)

Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK; Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge School of Clinical Medicine, Cambridge Biomedical Campus, Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH